or Try an Advanced Search...

    Treprostinil Stocks List

    Symbol Grade Name % Change
    UTHR C United Therapeutics Corporation 1.51
    LQDA D Liquidia Technologies, Inc. 4.93
    ASND D Ascendis Pharma A/S 5.85
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C

    Related ETFs - A few ETFs which own one or more of the above listed Treprostinil stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 17.04
    PBE C PowerShares Dynamic Biotech & Genome 5.74
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 3.9
    PJP C PowerShares Dynamic Pharmaceuticals 3.7
    FBT C First Trust Amex Biotech Index Fund 3.64
    View all Treprostinil ETFs...
    Compare ETFs
    Compare FTXH to FBT Compare MEDI to FTXH Compare PBE to FTXH

        Treprostinil Stocks Recent News

        Date Stock Title
        Nov 20 UTHR Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
        Nov 19 LQDA 3 US Growth Stocks With At Least 10% Insider Ownership
        Related Industries: Biotechnology
        Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C
        Treprostinil

        Treprostinil (marketed under the trade names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).
        The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.

        More about Treprostinil
        Browse All Tags